Find A Multiple Myeloma Trial
Search for a multiple myeloma clinical trial. You may need to satisfy additional criteria in order to be eligible for a study.

Talk With a Patient Navigator
For additional support click here to get connected with a patient navigator. Learn More About Clinical Trials

CLINICAL TRIAL FUND

Keyword Search
Zip Code
Condition Status
For assistance with trials outside the United States, please contact patientnavigator@themmrf.org
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
NCT06171685
Age 18 - 99
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach that combines different therapies to improve outcomes for patients. What makes this trial unique is its focus on using a combination of existing treatments in a novel way, which may enhance effectiveness and reduce side effects. This innovative strategy aims to provide better management options for patients facing challenges with their current treatment regimens.
Third Opinion AI Generated Synopsis

Sponsored By Multiple Myeloma Research Foundation
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT02199665
Age 18 +
Sex Both
Phase Phase 1
This study is testing the safety and effectiveness of combining selinexor, carfilzomib, and dexamethasone to treat multiple myeloma that has returned or is not responsive to other treatments. These drugs work in different ways to stop cancer cells from growing, dividing, or spreading.
Third Opinion AI Generated Synopsis

Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
NCT02291848
Age 18 +
Sex Both
Phase Phase 1
The study aims to use T lymphocytes to target tumor associated antigens (TAAs) in patients with Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). Its purpose is to determine the safety and effectiveness of this experimental therapy, with the goal of arresting the progression of the patient's condition to multiple myeloma.
Third Opinion AI Generated Synopsis

Selinexor and Backbone Treatments of Multiple Myeloma Patients
NCT02343042
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining multiple therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to evaluate how well these combined treatments work compared to standard options, providing hope for improved management of the condition.
Third Opinion AI Generated Synopsis

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
NCT03275103
Age 18 +
Sex Both
Phase Phase 1
This is a study where the drug cevostamab is given to patients with relapsed or refractory multiple myeloma through an IV infusion. The study aims to test the safety and effectiveness of different doses of cevostamab.
Third Opinion AI Generated Synopsis

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
NCT03601078
Age 18 +
Sex Both
Phase Phase 2
A study will be conducted to evaluate the efficacy and safety of bb2121 in subjects with multiple myeloma who have relapsed, progressed within a certain time frame, or have had an inadequate response to prior treatments. The study will enroll approximately 235 subjects across three cohorts, and will also include newly diagnosed multiple myeloma participants with suboptimal response to autologous stem cell transplantation.
Third Opinion AI Generated Synopsis

High Dose Ascorbic Acid for Plasma Cell Disorders
NCT03602235
Age 18 +
Sex Both
Phase Phase 1
The study is testing the safety and effectiveness of a combination of low dose melphalan and high dose ascorbate acid in patients with multiple myeloma who have already relapsed or become resistant to previous treatments. It is a Phase I clinical trial.
Third Opinion AI Generated Synopsis

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
NCT03710421
Age 18 +
Sex Both
Phase Phase 1
The study is testing the side effects and appropriate dosage of a therapy called CS1-CAR T, which modifies immune cells to kill cancer cells in patients with CS1-positive multiple myeloma that has relapsed or not responded well to previous treatments. CS1-CAR T cells are engineered immune cells that recognize and eliminate cancer cells.
Third Opinion AI Generated Synopsis

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
NCT04176718
Age 18 - 80
Sex Both
Phase Phase 2
The study aims to evaluate the effectiveness of combining daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in treating people with relapsed and refractory Multiple Myeloma, a condition in which previously treated Multiple Myeloma returns or becomes resistant to treatment.
Third Opinion AI Generated Synopsis

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
NCT04302324
Age 18 - 75
Sex Both
Phase Phase 2
This study will test a new treatment for relapsed/refractory multiple myeloma using daratumumab in combination with clarithromycin/pomalidomide/dexamethasone until progressive disease or unacceptable toxicity occurs, with the hypothesis that this combination will yield higher Very Good Partial Response rates than the historical pomalidomide/dexamethasone treatment.
Third Opinion AI Generated Synopsis

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
NCT04405167
Age 18 +
Sex Both
Phase Phase 1
The study is the first to examine the effects of tasquinimod, an inhibitor of S100A9, in people with multiple myeloma.
Third Opinion AI Generated Synopsis

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623
Age 18 +
Sex Both
Phase Phase 3
The study will compare the effectiveness and safety of belantamab mafodotin combined with pomalidomide and dexamethasone to a combination of pomalidomide, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.
Third Opinion AI Generated Synopsis

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
NCT04653246
Age 75 +
Sex Both
Phase Phase 2
The study is evaluating if isatuximab combined with usual treatments is safe and useful for newly diagnosed multiple myeloma patients.
Third Opinion AI Generated Synopsis

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
NCT04731844
Age 18 +
Sex Both
Phase Phase 2
This study aims to investigate the effects of curcumin and piperine supplementation, taken twice daily at a specific dosage, on early-stage prostate cancer patients under active surveillance or patients with MGUS/low-risk smoldering myeloma who are being monitored.
Third Opinion AI Generated Synopsis

Selinexor, Pomalidomide, and Dexamethasone with or Without Carfilzomib for the Treatment of Patients with Relapsed Refractory Multiple Myeloma, the SCOPE Trial
NCT04764942
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to evaluate how well this combination works compared to standard treatments, providing hope for improved management of the condition.
Third Opinion AI Generated Synopsis

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
NCT04876248
Age 18 +
Sex Both
Phase Phase 2
This trial is examining how the combination of belantamab mafodotin and lenalidomide affects patients with multiple myeloma who still have small amounts of cancer after a stem cell transplant. By targeting specific receptors on cancer cells and delivering a chemotherapy drug, belantamab mafodotin may help kill these cells, while lenalidomide may prevent further cancer growth. The goal is to keep the disease at very low levels in patients.
Third Opinion AI Generated Synopsis

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
NCT04879043
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on using a combination of therapies that target the disease in different ways, potentially improving patient outcomes. The study aims to assess how well this innovative treatment works compared to standard options.
Third Opinion AI Generated Synopsis

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT04883242
Age 18 +
Sex Both
Phase Phase 2
This trial tests the effectiveness of a treatment consisting of a monoclonal antibody, a protein blocker, a tumor cell growth inhibitor, and an anti-inflammatory drug in patients with multiple myeloma that has relapsed or is unresponsive to treatment. The treatment aims to kill more cancer cells by interfering with their growth and spread.
Third Opinion AI Generated Synopsis

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
NCT04960579
Age 18 +
Sex Both
Phase Phase 1
The study involved testing of P-BCMA-ALLO1 allogeneic T stem cell memory CAR-T cells in several groups of individuals with relapsed or refractory Multiple Myeloma. The study is the first phase of a larger clinical trial involving the CAR-T cells.
Third Opinion AI Generated Synopsis

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997
Age 18 +
Sex Both
Phase Phase 3
This study aims to compare the effectiveness and safety of two different treatments for relapsed or refractory multiple myeloma. One treatment includes iberdomide, dexamethasone and daratumumab, while the other includes daratumumab, bortezomib, and dexamethasone.
Third Opinion AI Generated Synopsis

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
NCT04991103
Age 18 +
Sex Both
Phase Phase 2
This study aims to determine if minimal residual disease detection through next-generation sequencing can delay autologous hematopoietic stem cell transplantation in patients newly diagnosed with multiple myeloma in phase II clinical trials. The goal is to assess whether this technique is a viable alternative treatment option to traditional AHCT.
Third Opinion AI Generated Synopsis

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
NCT05007418
Age 18 +
Sex Both
Phase Phase 1
This is a clinical trial where the drug STI-1492 is given to people with multiple myeloma who have not responded to previous treatments. The drug is administered intravenously in increasing amounts to determine the best dosage.
Third Opinion AI Generated Synopsis

TriPRIL CAR T Cells in Multiple Myeloma
NCT05020444
Age 18 +
Sex Both
Phase Phase 1
The study aims to test TriPRIL CAR T Cells for treating people with multiple myeloma and evaluate any side effects, along with standard chemotherapy drugs used in the treatment process.
Third Opinion AI Generated Synopsis

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
NCT05090566
Age 18 +
Sex Both
Phase Phase 2
The study aims to find the recommended dose and clinical impact of elranatamab when used in combination with other anti-cancer therapies for treating multiple myeloma patients.
Third Opinion AI Generated Synopsis

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
NCT05137054
Age 18 +
Sex Both
Phase Phase 1
This study focuses on a unique approach to treating patients by combining multiple therapies to enhance effectiveness. It aims to improve patient outcomes by utilizing a specific combination of treatments that target the disease more effectively. This innovative strategy may offer new hope for those seeking better management options.
Third Opinion AI Generated Synopsis

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05257083
Age 18 +
Sex Both
Phase Phase 3
In this study, researchers are exploring a new treatment approach for patients with Multiple Myeloma that combines different therapies to enhance effectiveness. What makes this trial unique is its focus on using a combination of established treatments in a novel way, potentially leading to better outcomes for patients. The study aims to assess how well this combination works compared to standard treatments, providing hope for improved management of the condition.
Third Opinion AI Generated Synopsis

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05259839
Age 18 +
Sex Both
Phase Phase 1
The study will assess the safety and toxicity of investigational drug ABBV-383 when given with other medications to adult patients with relapsed/refractory multiple myeloma. The study will include a dose escalation and dose expansion phase, with approximately 270 participants at sites worldwide, and treatment burden may be higher than standard of care.
Third Opinion AI Generated Synopsis

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
NCT05372354
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique approach to treatment by combining different therapies to enhance effectiveness against the disease. The trial focuses on using a specific combination of medications that have shown promise in previous studies, aiming to improve patient outcomes. This innovative strategy may offer new hope for individuals seeking effective treatment options.
Third Opinion AI Generated Synopsis

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
NCT05427812
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique approach to treating patients with Multiple Myeloma by using a combination of therapies that target specific pathways involved in the disease. This study stands out because it focuses on a personalized treatment plan that adapts to the individual needs of each patient, potentially leading to more effective outcomes. By integrating various treatment modalities, the study aims to improve the overall management of the condition and enhance patients' quality of life.
Third Opinion AI Generated Synopsis

A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
NCT05431608
Age 18 +
Sex Both
Phase Phase 1
Participants' T cells will be turned into study therapies MCARH109 and MCARH125. Participants will get either MCARH125 by itself or MCARH125 combined with MCARH109.
Third Opinion AI Generated Synopsis

A Study of Daratumumab
NCT05438043
Age Any Age.
Sex Both
Phase Phase 3
This study aims to give continuous access to treatment for participants with multiple myeloma or smoldering multiple myeloma who have benefited from daratumumab studies. It will also collect long-term safety data from the participants.
Third Opinion AI Generated Synopsis

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
NCT05469893
Age 18 +
Sex Both
Phase Phase 2
This study aims to compare Teclistamab with Lenalidomide + Dexamethasone in individuals with high risk smoldering multiple myeloma to test the anti-cancer activity of Teclistamab. Smoldering multiple myeloma is a condition where individuals are at risk for developing active multiple myeloma and no approved therapies currently exist for it.
Third Opinion AI Generated Synopsis

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
NCT05497804
Age 18 - 80
Sex Both
Phase Phase 2
This trial tests whether a combination of chemotherapy drugs can improve blood test results in patients with high-risk multiple myeloma by killing, stopping the growth of or preventing the spread of cancer cells. It will also investigate if patients with minimal residual disease will benefit from this drug combination.
Third Opinion AI Generated Synopsis

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
NCT05514990
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to evaluate how well this combination works compared to standard treatments, providing hope for improved management of the condition.
Third Opinion AI Generated Synopsis

LMY-920 for Treatment of Relapsed or Refractory Myeloma
NCT05546723
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a new treatment approach for patients with Multiple Myeloma that involves a combination of therapies aimed at enhancing the immune response. What makes this trial unique is its focus on using a specific type of immune cell activation alongside traditional treatments, which may lead to improved outcomes. This innovative strategy could potentially offer a more effective way to manage the disease and improve patient quality of life.
Third Opinion AI Generated Synopsis

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
NCT05561387
Age Any Age.
Sex Both
Phase Phase 3
In a phase III trial, researchers are comparing three different drug combinations for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and considered frail or intermediate-fit. The goal is to determine which combination of drugs is more effective in shrinking and controlling the cancer.
Third Opinion AI Generated Synopsis

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515
Age 18 +
Sex Both
Phase Phase 3
This study aims to determine if teclistamab is as effective as PVd/Kd for a specific purpose.
Third Opinion AI Generated Synopsis

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
NCT05597345
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a unique treatment approach for patients with Multiple Myeloma by using a combination of therapies that target specific pathways involved in the disease. This study stands out because it focuses on personalized treatment plans based on individual patient characteristics, which may lead to more effective outcomes. By investigating how these tailored therapies can improve patient responses, the study aims to enhance the overall management of the condition.
Third Opinion AI Generated Synopsis

A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT05650632
Age 18 +
Sex Both
Phase Phase 1
This study is testing a new drug, ABBV-383, for the treatment of relapsed/refractory Multiple Myeloma. The study will enroll around 80 adult participants who will receive the drug through an infusion in 28 day cycles for approximately 3 years. Regular visits, medical assessments, blood tests, and questionnaires will be conducted to assess the treatment's effectiveness and any side effects.
Third Opinion AI Generated Synopsis

A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma
NCT05651932
Age 18 +
Sex Both
Phase Phase 1
This study aims to test the safety of a new orally available drug that can inhibit an enzyme called MMSET in patients with relapsed or refractory multiple myeloma, a type of cancer, by preventing a specific chemical modification in cells.
Third Opinion AI Generated Synopsis

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036
Age 18 +
Sex Both
Phase Phase 3
In this clinical study, researchers are exploring a unique treatment approach that combines multiple therapies to target specific aspects of the disease. This study stands out because it focuses on a combination of existing treatments and new strategies to enhance patient outcomes. By investigating how these therapies work together, the study aims to improve the effectiveness of treatment for patients.
Third Opinion AI Generated Synopsis

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
NCT05789303
Age 18 +
Sex Both
Phase Phase 2
In this study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to evaluate how well these combined treatments work compared to standard options.
Third Opinion AI Generated Synopsis

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016
Age 18 +
Sex Both
Phase Phase 3
This study aims to investigate if iberdomide maintenance therapy is more effective than lenalidomide maintenance therapy after autologous stem cell transplantation in individuals with newly diagnosed multiple myeloma.
Third Opinion AI Generated Synopsis

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
NCT05828511
Age 18 +
Sex Both
Phase Phase 1, Phase 2
This clinical study focuses on a unique approach to treating patients by combining different treatment strategies to enhance effectiveness. It aims to evaluate the safety and efficacy of a specific regimen that includes both established and novel therapies, potentially leading to improved outcomes for patients. The study also emphasizes the importance of personalized treatment plans tailored to individual patient needs.
Third Opinion AI Generated Synopsis

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
NCT05847569
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness and improve patient outcomes. The study aims to assess how well this combination works compared to standard treatments, potentially offering a more effective option for managing the disease.
Third Opinion AI Generated Synopsis

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
NCT05850234
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies that target the disease in innovative ways, potentially improving patient outcomes. This trial is distinctive because it involves a multi-faceted treatment strategy that aims to enhance the effectiveness of existing therapies.
Third Opinion AI Generated Synopsis

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma
NCT05862012
Age 18 +
Sex Both
Phase Phase 1
In this study, researchers are exploring a new treatment approach that combines different therapies to target Multiple Myeloma more effectively. What makes this trial unique is its focus on using a specific combination of drugs that have shown promise in earlier studies, aiming to improve patient outcomes. Participants will receive personalized treatment plans based on their individual responses, which could lead to more tailored and effective care.
Third Opinion AI Generated Synopsis

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
NCT05892393
Age 18 +
Sex Both
Phase Phase 1
This trial is evaluating the safety and efficacy of [89Zr]DFO-YS5 PET imaging in detecting CD46 positive cancer cells in patients with multiple myeloma. [89Zr]DFO-YS5 is a radiopharmaceutical tracer that targets CD46 and may enhance the detection of multiple myeloma.
Third Opinion AI Generated Synopsis

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients with Relapsed/Refractory Multiple Myeloma
NCT05896228
Age 18 - 75
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to evaluate how well this combination works compared to standard treatments, providing valuable insights into more effective care options.
Third Opinion AI Generated Synopsis

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
NCT05911321
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach that combines different therapies to improve outcomes for patients. What makes this trial unique is its focus on a specific combination of treatments that target the disease in innovative ways, potentially leading to better management of symptoms and improved quality of life. The study aims to gather valuable data on how these treatments work together, which could pave the way for more effective options in the future.
Third Opinion AI Generated Synopsis

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
NCT05972135
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness and improve patient outcomes. The study aims to evaluate how well these combined treatments work compared to standard options, potentially offering new hope for better management of the condition.
Third Opinion AI Generated Synopsis

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
NCT05981209
Age 18 +
Sex Both
Phase Phase 1
This clinical study focuses on a unique treatment approach for patients with Multiple Myeloma by utilizing a combination of therapies that target specific pathways involved in the disease. It aims to improve patient outcomes by enhancing the effectiveness of existing treatments while minimizing side effects. The study also emphasizes the importance of personalized medicine, tailoring therapies to individual patient profiles for better results.
Third Opinion AI Generated Synopsis

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
NCT06042725
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a new treatment approach for patients with Multiple Myeloma that combines multiple therapies, including a specific class of medications and a unique delivery method. What makes this trial stand out is its focus on using a combination of therapies to enhance effectiveness and potentially improve patient outcomes. The study aims to assess how well this innovative treatment works compared to standard options, providing hope for better management of the condition.
Third Opinion AI Generated Synopsis

Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
NCT06048250
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining multiple therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to assess how well this combination works compared to standard treatments, providing valuable insights into more effective care options.
Third Opinion AI Generated Synopsis

Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
NCT06050512
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness and improve patient outcomes. The study aims to assess how well these combined treatments work in managing the disease and potentially offering better options for patients.
Third Opinion AI Generated Synopsis

Teclistamab or Talquetamab in Combination with Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study)
NCT06100237
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach that combines two therapies to enhance patient outcomes. What makes this trial unique is its focus on a specific combination of treatments that may improve effectiveness and reduce side effects for patients. This innovative strategy aims to provide a more personalized treatment option for individuals facing this condition.
Third Opinion AI Generated Synopsis

18F-Fluciclovine PET/CT in Multiple Myeloma
NCT06103838
Age 18 - 120
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with Multiple Myeloma that involves using a combination of therapies to enhance effectiveness. What makes this trial unique is its focus on integrating various treatment methods to improve patient outcomes and potentially reduce side effects. Participants will be closely monitored to assess the impact of this innovative strategy on their health and recovery.
Third Opinion AI Generated Synopsis

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
NCT06115135
Age Any Age.
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a unique combination of treatments for patients with a specific type of blood cancer. The study focuses on using a combination of therapies that have shown promise in previous trials, aiming to improve patient outcomes and potentially enhance the effectiveness of existing treatments. This innovative approach may offer new hope for patients by targeting the disease more effectively and reducing side effects.
Third Opinion AI Generated Synopsis

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
NCT06119685
Age 18 +
Sex Both
Phase Phase 1, Phase 2
This clinical study focuses on a unique combination of treatments for patients with Multiple Myeloma, utilizing a specific approach that integrates various therapies to enhance effectiveness. It aims to evaluate how well these combined treatments work in managing the condition and improving patient outcomes. The study also emphasizes the importance of personalized treatment plans tailored to individual patient needs.
Third Opinion AI Generated Synopsis

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843
Age 18 +
Sex Both
Phase Phase 1
This study focuses on a unique approach to treating patients by evaluating a specific combination of therapies that target the disease more effectively. It aims to enhance patient outcomes by using a tailored treatment plan that considers individual responses. The study also emphasizes the importance of monitoring and adjusting therapies based on real-time data from participants.
Third Opinion AI Generated Synopsis

Elranatamab in R/R Multiple Myeloma
NCT06138275
Age 18 +
Sex Both
Phase Phase 2
This clinical study focuses on a unique approach to treating Multiple Myeloma by utilizing a combination of therapies that target specific pathways involved in the disease. It aims to evaluate the effectiveness of this combination in improving patient outcomes and reducing disease progression. The study also emphasizes the importance of personalized treatment plans based on individual patient characteristics.
Third Opinion AI Generated Synopsis

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
NCT06140524
Age 18 +
Sex Both
Phase Phase 2
The study focuses on a unique approach to treating patients by combining different therapies to enhance effectiveness. It aims to evaluate the impact of this combination on the disease's progression and patient outcomes. By exploring various treatment strategies, the study seeks to provide new insights into managing the condition more effectively.
Third Opinion AI Generated Synopsis

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06153251
Age 18 +
Sex Both
Phase Phase 1
This clinical study focuses on a unique approach to treating Multiple Myeloma by utilizing a combination of therapies that have shown promise in previous research. It aims to enhance patient outcomes by integrating innovative treatment strategies and monitoring their effectiveness closely. Participants will receive personalized care tailored to their specific needs, which may lead to improved management of their condition.
Third Opinion AI Generated Synopsis

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (CERVINO)
NCT06158841
Age 18 +
Sex Both
Phase Phase 3
In this study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness and improve patient outcomes. Participants will receive personalized treatment plans based on their individual responses, which may lead to more tailored and effective care.
Third Opinion AI Generated Synopsis

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
NCT06169215
Age Any Age.
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with Multiple Myeloma that combines a specific drug regimen with a unique delivery method. This trial is distinctive because it focuses on using a targeted therapy that aims to enhance the effectiveness of existing treatments while minimizing side effects. By investigating this innovative combination, the study hopes to improve patient outcomes and provide more personalized care options.
Third Opinion AI Generated Synopsis

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
NCT06179888
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a unique approach to treating patients with a specific type of blood cancer by using a combination of therapies that target the disease in innovative ways. The study focuses on how these treatments can improve patient outcomes and potentially lead to better management of the condition. This trial is distinctive because it aims to personalize treatment plans based on individual patient responses, which may enhance effectiveness and reduce side effects.
Third Opinion AI Generated Synopsis

Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
NCT06185751
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a unique approach to treating Multiple Myeloma by using a combination of therapies that target specific pathways involved in the disease. The study focuses on the use of a new treatment regimen that includes both established and innovative therapies, aiming to improve patient outcomes and reduce side effects. This trial is distinctive because it emphasizes personalized treatment plans based on individual patient characteristics and disease profiles.
Third Opinion AI Generated Synopsis

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT06203912
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to assess how well this combination works compared to standard treatments, providing valuable insights into more effective care options.
Third Opinion AI Generated Synopsis

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
NCT06215118
Age 18 +
Sex Both
Phase Phase 1
In this study, researchers are exploring a unique combination treatment for patients, which includes a specific type of therapy that targets the cancer cells more effectively. The trial focuses on how this combination can improve patient outcomes and potentially lead to better management of the condition. By using a novel approach, the study aims to enhance the effectiveness of existing treatments and provide new options for patients.
Third Opinion AI Generated Synopsis

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06223516
Age 18 +
Sex Both
Phase Phase 1
In this study, researchers are exploring a unique approach to treating patients by using a combination of therapies that target specific aspects of the disease. The trial focuses on the use of advanced techniques to enhance the effectiveness of treatment, potentially leading to better outcomes for patients. This innovative strategy aims to improve the overall management of the condition and may offer new hope for those affected.
Third Opinion AI Generated Synopsis

A Trial of Selinexor, Ruxolitinib and Methylprednisolone
NCT06225310
Age Any Age.
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a unique treatment approach that combines a specific drug with a targeted delivery method to enhance its effectiveness against Multiple Myeloma. This study stands out because it focuses on using advanced techniques to improve how the drug reaches the cancer cells, potentially leading to better outcomes for patients. By investigating this innovative strategy, the study aims to provide new options for managing the disease more effectively.
Third Opinion AI Generated Synopsis

Hypofractionation (Radiation) Trial for Multiple Myeloma
NCT06270888
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a unique treatment approach for patients with a specific type of blood cancer. The study focuses on a combination of therapies that aim to enhance the effectiveness of existing treatments, potentially leading to better outcomes for patients. This innovative strategy may provide new options for those who have not responded well to standard therapies.
Third Opinion AI Generated Synopsis

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06297226
Age 18 +
Sex Both
Phase Phase 2
In this study, researchers are exploring a new treatment approach for patients with Multiple Myeloma that combines different therapies to enhance effectiveness. What makes this trial unique is its focus on using a specific combination of drugs that have shown promise in previous studies, aiming to improve patient outcomes. The study also emphasizes the importance of personalized treatment plans tailored to individual patient needs.
Third Opinion AI Generated Synopsis

Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
NCT06304636
Age 18 +
Sex Both
Phase Phase 1
This study focuses on a unique approach to treating patients with Multiple Myeloma by evaluating the effectiveness of a specific combination therapy. It aims to enhance patient outcomes by targeting the disease more effectively and improving overall treatment responses. The trial also emphasizes the importance of patient participation and the potential for personalized treatment strategies.
Third Opinion AI Generated Synopsis

ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT06351644
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on a combination of therapies that have not been widely tested together before, potentially offering a more effective treatment option. The study aims to evaluate how well this new combination works in improving patient outcomes compared to standard treatments.
Third Opinion AI Generated Synopsis

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
NCT06381141
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a unique treatment approach for patients with Multiple Myeloma by using a combination of therapies that target specific aspects of the disease. The study focuses on the effectiveness of this combination in improving patient outcomes and aims to provide insights into how these treatments can be tailored for better results. This innovative strategy may offer new hope for patients by enhancing the overall management of their condition.
Third Opinion AI Generated Synopsis

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
NCT06433947
Age 18 +
Sex Both
Phase Phase 1
In this study, researchers are exploring a new treatment approach that combines different therapies to enhance effectiveness against the disease. What makes this trial unique is its focus on using a combination of agents that target multiple pathways, potentially leading to better outcomes for patients. This innovative strategy aims to improve the overall management of the condition and may offer new hope for those affected.
Third Opinion AI Generated Synopsis

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
NCT06465316
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness and improve patient outcomes. The study aims to assess how well this combination works compared to standard treatments, potentially offering a more effective option for managing the disease.
Third Opinion AI Generated Synopsis

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
NCT06518551
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach that combines a specific type of antibody with a well-known medication to enhance its effectiveness against Multiple Myeloma. What makes this trial unique is its focus on using a combination therapy that targets the disease in a novel way, potentially leading to better outcomes for patients. The study aims to evaluate how well this combination works and its safety profile, providing valuable insights into future treatment options.
Third Opinion AI Generated Synopsis

ATRA and Carfilzomib in Plasma Cell Myeloma Patients
NCT06536413
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique treatment approach for patients with Multiple Myeloma by combining different therapies to enhance effectiveness. The study focuses on using a specific combination of medications that target the disease in innovative ways, potentially leading to improved outcomes for patients. This trial aims to provide insights into how these combined treatments can better manage the condition and improve patient quality of life.
Third Opinion AI Generated Synopsis

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
NCT06550895
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a unique treatment approach that combines a specific type of cell therapy with a targeted drug to improve outcomes for patients. This study focuses on patients who have a particular type of disease progression, aiming to enhance their response to treatment. By using a combination of therapies, the study seeks to provide a more effective way to manage the condition and potentially improve patient quality of life.
Third Opinion AI Generated Synopsis

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
NCT06582017
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a unique combination of therapies to treat patients with Multiple Myeloma. The study focuses on using a specific approach that combines different treatment methods, aiming to enhance effectiveness and improve patient outcomes. This innovative strategy may provide new options for managing the condition and could lead to better responses in patients who have not had success with standard treatments.
Third Opinion AI Generated Synopsis

ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT06588660
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a unique treatment approach for patients with Multiple Myeloma by combining different therapies to enhance effectiveness. The study focuses on a specific combination of medications that may improve patient outcomes and reduce side effects compared to traditional treatments. This innovative strategy aims to provide a more personalized treatment plan tailored to individual patient needs.
Third Opinion AI Generated Synopsis

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479
Age 18 +
Sex Both
Phase Phase 3
In this clinical study, researchers are exploring a unique approach to treating Multiple Myeloma by combining different therapies, including a specific type of antibody treatment. This study stands out because it focuses on the effectiveness of these combinations in patients who have already undergone other treatments. The goal is to improve patient outcomes and provide new options for those with this condition.
Third Opinion AI Generated Synopsis

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT06622005
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a unique combination treatment for patients with a specific type of blood cancer. The study focuses on using a combination of therapies that have not been previously tested together, aiming to improve patient outcomes. This innovative approach may provide new options for managing the disease and enhancing the quality of life for those affected.
Third Opinion AI Generated Synopsis

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
NCT06623630
Age 18 +
Sex Both
Phase Phase 1
This clinical study focuses on a unique approach to treating Multiple Myeloma by using a combination of therapies that target specific pathways involved in the disease. It aims to improve patient outcomes by integrating innovative treatment strategies and personalized care plans. Participants will receive tailored interventions designed to enhance their overall health and response to therapy.
Third Opinion AI Generated Synopsis

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
NCT06785415
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique treatment approach for patients with a specific type of blood cancer. The study focuses on a combination of therapies that may enhance the effectiveness of existing treatments, potentially leading to better outcomes for patients. This innovative strategy aims to improve patient responses and overall health by targeting the disease more effectively.
Third Opinion AI Generated Synopsis

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
NCT04211259
Age 18 +
Sex Both
Phase Early Phase 1
This study focuses on a unique approach to treating patients by combining multiple therapies to enhance effectiveness. It aims to improve patient outcomes by utilizing a specific treatment regimen that targets the disease more aggressively. Participants will receive a tailored treatment plan that may lead to better management of their condition.
Third Opinion AI Generated Synopsis

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
NCT05231629
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with Multiple Myeloma that combines multiple therapies to enhance effectiveness. What makes this trial unique is its focus on using a combination of therapies that have not been previously tested together, potentially leading to improved outcomes. The study aims to assess how well this innovative treatment can help manage the disease and improve patients' quality of life.
Third Opinion AI Generated Synopsis

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
NCT05392946
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness and improve patient outcomes. The study aims to assess how well this combination works in managing the disease and potentially offers a new option for patients who have not responded well to existing treatments.
Third Opinion AI Generated Synopsis

CAR- PRISM (PRecision Intervention Smoldering Myeloma)
NCT05767359
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on using a combination of therapies that target the cancer cells more effectively while minimizing side effects. This innovative strategy aims to improve patient outcomes and enhance the overall quality of life for those affected.
Third Opinion AI Generated Synopsis

MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
NCT06171685
Age 18 - 99
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach that combines different therapies to improve outcomes for patients. What makes this trial unique is its focus on using a combination of existing treatments in a novel way, which may enhance effectiveness and reduce side effects. This innovative strategy aims to provide better management options for patients facing challenges with their current treatment regimens.
Third Opinion AI Generated Synopsis

Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine
NCT03762291
Age 18 +
Sex Both
Phase Phase 1
Multiple myeloma patients will receive an investigational cancer vaccine called TXSVN, derived from a weakened form of the Salmonella bacteria that has been genetically modified in the laboratory to produce a protein known as Survivin. The vaccine aims to activate the immune system and develop a response against cancer cells that contain Survivin, with the aim of finding a safe dose, monitoring side effects, and assessing any potential benefits of the therapy.
Third Opinion AI Generated Synopsis

A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
NCT05393804
Age 18 +
Sex Both
Phase Phase 2
This study aims to investigate whether the quality of T cells used to produce a therapy called ide-cel affects its ability to prevent the recurrence of multiple myeloma in patients who have previously received a hematopoietic cell transplant for the disease. The focus is on determining whether ide-cel's efficacy varies based on the composition of T cells used in its creation.
Third Opinion AI Generated Synopsis

Elranatamab in Relapsed/Refractory Multiple Myeloma
NCT06711705
Age 18 +
Sex Both
Phase Phase 2
This clinical study focuses on a unique treatment approach for patients with Multiple Myeloma, utilizing a combination of therapies that have shown promise in previous research. It aims to evaluate the effectiveness of this combination in improving patient outcomes and reducing disease progression. The study also emphasizes the importance of patient participation and the potential for personalized treatment plans based on individual responses.
Third Opinion AI Generated Synopsis

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT04508790
Age 18 +
Sex Both
Phase Phase 2
This phase II trial looks at how well leflunomide, pomalidomide, and dexamethasone work for treating multiple myeloma that has come back or does not respond to treatment. The combination of these drugs may work better than using pomalidomide and dexamethasone alone, by blocking cancer cell growth, inducing changes in the body's immune system, and stopping the growth and spread of tumor cells.
Third Opinion AI Generated Synopsis

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT03091257
Age 18 +
Sex Both
Phase Phase 1
The study aims to investigate whether Trametinib and Dabrafenib could be effective treatments for multiple myeloma.
Third Opinion AI Generated Synopsis

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
NCT05002816
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness and improve patient outcomes. The study aims to evaluate how well these combined treatments work compared to standard options, potentially offering new hope for better management of the condition.
Third Opinion AI Generated Synopsis

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
NCT05091372
Age 18 +
Sex Both
Phase Phase 2
This study aimed to improve the rate of remission in patients with newly diagnosed multiple myeloma who tested positive for minimal residual disease (MRD) by using belantamab mafodotin and lenalidomide as maintenance therapy after a transplant.
Third Opinion AI Generated Synopsis

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
NCT06523621
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on using a combination of therapies that have not been widely tested together before, potentially leading to more effective outcomes. The study aims to evaluate how well this new treatment can improve patient responses and overall health.
Third Opinion AI Generated Synopsis

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
NCT04268498
Age 18 - 75
Sex Both
Phase Phase 2
The study aims to determine the safety and effectiveness of KRD or KRD+DARA in controlling multiple myeloma compared to the current standard treatment, VRD. The goal is to find a better treatment option.
Third Opinion AI Generated Synopsis

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
NCT05014646
Age 18 +
Sex Both
Phase Phase 2
The trial is examining if leflunomide can delay the symptoms of high-risk smoldering multiple myeloma in both African-American and European-American patients by decreasing the immune response of the body. It's a phase II trial.
Third Opinion AI Generated Synopsis

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
NCT05396885
Age 18 +
Sex Both
Phase Phase 2
A Phase II study evaluated the effectiveness of CART-ddBCMA, a CAR-T cell therapy directed towards BCMA, in patients with relapsed or refractory multiple myeloma, a type of cancer. This study aimed to assess if CART-ddBCMA could be a potential treatment option for these patients.
Third Opinion AI Generated Synopsis

A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function
NCT04398680
Age 18 +
Sex Both
Phase Phase 1
The study aims to evaluate the safety and effectiveness of belantamab mafodotin as a treatment for Relapsed/Refractory Multiple Myeloma in participants with and without liver impairment. The focus is on assessing the drug's pharmacokinetics, safety, and tolerability.
Third Opinion AI Generated Synopsis

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
NCT04519476
Age 18 +
Sex Both
Phase Phase 1
This study aims to test whether selinexor is safe and effective in treating multiple myeloma patients who have not responded to a treatment involving lenalidomide, with or without steroids.
Third Opinion AI Generated Synopsis

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed And/or Refractory Multiple Myeloma
NCT04835129
Age 18 +
Sex Both
Phase Phase 2
The study aims to test the effectiveness of a combination of isatuximab, elotuzumab, pomalidomide, and dexamethasone in treating multiple myeloma. The trial includes patients who have relapsed and received at least two prior treatments.
Third Opinion AI Generated Synopsis

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
NCT05405387
Age 18 +
Sex Both
Phase Phase 2
This study aims to assess the effectiveness of budesonide in multiple myeloma patients undergoing stem cell transplant by comparing it to a placebo, with a run-in period involving 20 patients.
Third Opinion AI Generated Synopsis

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
NCT05675449
Age 18 +
Sex Both
Phase Phase 1
In this clinical trial, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this study unique is its focus on combining different therapies to enhance effectiveness and improve patient outcomes. Participants will receive a tailored treatment plan that may offer new hope for managing their condition.
Third Opinion AI Generated Synopsis

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
NCT05722418
Age 18 +
Sex Both
Phase Phase 1
This study aims to test a new treatment called CB-011, which uses CAR-T cell therapy to target a specific protein in multiple myeloma. The study will evaluate the safety, dosage, and effectiveness of CB-011 in patients with relapsed or refractory multiple myeloma.
Third Opinion AI Generated Synopsis

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
NCT06057402
Age 18 +
Sex Both
Phase Phase 4
This clinical study focuses on a unique approach to treating patients with Multiple Myeloma by using a specific combination of therapies that target the disease in innovative ways. It aims to improve patient outcomes by exploring new treatment options that have not been widely tested before. The study also emphasizes the importance of personalized treatment plans tailored to individual patient needs.
Third Opinion AI Generated Synopsis

Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
NCT06107738
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to assess how well this combination works compared to standard treatments, providing valuable insights into more effective care options.
Third Opinion AI Generated Synopsis

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
NCT06376526
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness, particularly in patients who have not responded well to standard treatments. The study aims to assess how well this combination therapy works in improving patient outcomes and overall health.
Third Opinion AI Generated Synopsis

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
NCT03570983
Age 18 - 70
Sex Both
Phase Phase 2
This study aims to compare the effectiveness of Melphalan and BEAM treatment in Multiple Myeloma patients. The study is deemed ethical because BEAM has been previously studied for safety and toxicity, and early retrospective data suggests BEAM may be effective in MM.
Third Opinion AI Generated Synopsis

Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma
NCT03761108
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on a combination of therapies that aim to enhance the effectiveness of existing treatments while minimizing side effects. This innovative strategy could potentially lead to improved outcomes for patients by targeting the disease more effectively.
Third Opinion AI Generated Synopsis

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
NCT04091126
Age 18 +
Sex Both
Phase Phase 1
The study will test the safety, effectiveness, and recommended dosage of a drug called belantamab mafodotin when used in combination with other drugs to treat newly diagnosed multiple myeloma. Participants will receive a combination of drugs on a specific schedule and will be monitored for safety after completing the treatment.
Third Opinion AI Generated Synopsis

A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
NCT04398745
Age 18 +
Sex Both
Phase Phase 1
This study aims to evaluate the safety and effectiveness of belantamab mafodotin, an anti-cancer drug, in patients with multiple myeloma who have renal impairment. The study will be conducted in two parts, with participants receiving the drug at a dose of either 2.5mg/kg or 1.9mg/kg every three weeks until disease progression or other endpoints occur.
Third Opinion AI Generated Synopsis

Personalized Autologous Transplant for Multiple Myeloma
NCT04483206
Age 18 +
Sex Both
Phase Phase 1
This trial aims to find the best dose of mephalan for multiple myeloma patients undergoing stem cell transplant by analyzing their blood levels, which may help personalize the treatment and determine who will benefit the most. Mephalan, a chemotherapy drug, can stop the growth of cancer cells in different ways, including killing cells or stopping them from dividing or spreading.
Third Opinion AI Generated Synopsis

A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
NCT04497961
Age 18 +
Sex Both
Phase Phase 2
This study aims to compare the usual maintenance therapy for multiple myeloma (lenalidomide) with daratumumab as maintenance therapy to determine which drug provides a better quality of life during treatment for patients who have responded well to initial treatment. The study will measure participants' quality of life using questionnaires to determine whether daratumumab is a better, similar, or worse approach to maintenance therapy.
Third Opinion AI Generated Synopsis

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
NCT04640779
Age 18 +
Sex Both
Phase Phase 1
This trial is testing the safety and optimal dosage of combining choline salicylate and selinexor in patients with non-Hodgkin or Hodgkin lymphoma, multiple myeloma, or histiocytic/dendritic cell neoplasm. Choline salicylate is an anti-inflammatory drug that reduces immune response, while selinexor works by blocking a protein necessary for cancer cell growth. The study aims to provide more information about the effectiveness of this drug combination in treating these types of cancer.
Third Opinion AI Generated Synopsis

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
NCT04661137
Age 18 +
Sex Both
Phase Phase 2
This study will examine the response rate of patients with multiple myeloma receiving selinexor in combination with carfilzomib, daratumumab, or pomalidomide. Patients will be assigned to the groups based on their current treatment and will continue treatment until disease progression, death, toxicity, or withdrawal.
Third Opinion AI Generated Synopsis

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
NCT04756726
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique approach to treatment by combining different therapies to enhance effectiveness against the disease. The study focuses on using a specific combination of medications that target various aspects of the condition, potentially leading to improved patient outcomes. This innovative strategy aims to provide a more comprehensive treatment option for individuals facing this health challenge.
Third Opinion AI Generated Synopsis

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
NCT04822337
Age 18 +
Sex Both
Phase Phase 1, Phase 2
This clinical study focuses on a unique combination of treatments for patients, aiming to enhance the effectiveness of existing therapies. It explores the use of a specific drug regimen that targets multiple pathways involved in the disease, potentially leading to improved outcomes. By investigating this innovative approach, the study seeks to provide new options for managing the condition more effectively.
Third Opinion AI Generated Synopsis

Study of Magrolimab Combinations in Participants With Relapsed/Refractory Multiple Myeloma
NCT04892446
Age 18 +
Sex Both
Phase Phase 2
This study aims to evaluate the safety and efficacy of magrolimab in combination with other anticancer therapies for participants with relapsed/refractory multiple myeloma, with a focus on determining the recommended phase 2 dose and measuring the objective response rate.
Third Opinion AI Generated Synopsis

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
NCT04942067
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to evaluate how well this combination works compared to standard treatments.
Third Opinion AI Generated Synopsis

Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
NCT05065047
Age 18 +
Sex Both
Phase Phase 1
This clinical research aims to determine if the use of belantamab mafodotin (Blenrep) can prevent the recurrence of multiple myeloma in patients who have undergone an autologous stem cell transplant. The study will also analyze the safety of the drug in the post-transplant period.
Third Opinion AI Generated Synopsis

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
NCT05145400
Age 18 +
Sex Both
Phase Phase 2
This study is testing a combination of three drugs - isatuximab, lenalidomide, and dexamethasone - to treat newly diagnosed multiple myeloma. The study will use lower doses to reduce any unwanted side effects, but this combination is not currently approved by the FDA for this use.
Third Opinion AI Generated Synopsis

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797
Age 18 +
Sex Both
Phase Phase 3
This clinical study focuses on a unique approach to treating patients with Multiple Myeloma by using a combination of therapies that target the disease in innovative ways. It aims to evaluate the effectiveness of these treatments in improving patient outcomes and managing symptoms. The study also emphasizes the importance of personalized treatment plans tailored to individual patient needs.
Third Opinion AI Generated Synopsis

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416
Age 18 +
Sex Both
Phase Phase 3
In this study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness and improve patient outcomes. The study aims to evaluate how well these combined treatments work in managing the disease and potentially offering better options for patients.
Third Opinion AI Generated Synopsis

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
NCT05346809
Age 18 +
Sex Both
Phase Phase 2
This study will test whether Isatuximab can improve the immune system of patients with multiple myeloma or lymphoma after autologous stem cell transplantation, to better fight their cancer. Participants will be randomly assigned to two groups, with around two-thirds receiving Isatuximab in addition to the standard transplant procedure.
Third Opinion AI Generated Synopsis

Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
NCT05354557
Age 18 - 75
Sex Both
Phase Phase 2
The study aims to determine if iberdomide can be a safe and effective maintenance therapy for individuals with Multiple Myeloma who have undergone an Autologous Hematopoietic Stem Cell Transplant and have previously received lenalidomide therapy.
Third Opinion AI Generated Synopsis

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085
Age 18 +
Sex Both
Phase Phase 3
This study aims to compare the effectiveness and safety of CC-92480, bortezomib, and dexamethasone with pomalidomide, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma who have undergone 1 to 3 prior treatment lines and experienced lenalidomide exposure.
Third Opinion AI Generated Synopsis

VitD3 Supplementation in Patients With Multiple Myeloma
NCT05846880
Age 18 +
Sex Both
Phase Early Phase 1
In this clinical study, researchers are exploring a unique treatment approach for patients with Multiple Myeloma by using a combination of therapies that target the disease in different ways. This study stands out because it focuses on a specific patient population and aims to evaluate the effectiveness of these treatments over a defined period. The goal is to improve patient outcomes and provide new options for managing this condition.
Third Opinion AI Generated Synopsis

Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
NCT06052826
Age 60 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a unique approach to treating patients by using a combination of therapies that target specific aspects of the disease. The study focuses on a new method that combines different treatment strategies to enhance effectiveness and improve patient outcomes. This innovative approach aims to provide a more personalized treatment plan for individuals, potentially leading to better management of their condition.
Third Opinion AI Generated Synopsis

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
NCT06055075
Age 18 +
Sex Both
Phase Phase 1, Phase 2
The study focuses on a unique approach to treating patients by combining various therapies to enhance effectiveness. It aims to evaluate the safety and effectiveness of these combinations, which may lead to improved outcomes for individuals. This innovative strategy could provide new options for managing the condition more effectively.
Third Opinion AI Generated Synopsis

A Study of Talquetamab for People with Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
NCT06066346
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a unique treatment approach for patients with a specific type of blood cancer. The study focuses on a combination therapy that aims to enhance the effectiveness of existing treatments by targeting multiple pathways involved in the disease. This innovative strategy may provide new options for patients who have not responded well to standard therapies.
Third Opinion AI Generated Synopsis

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
NCT06142396
Age 18 - 80
Sex Both
Phase Early Phase 1
In this clinical study, researchers are exploring a new treatment approach for patients with Multiple Myeloma that involves a combination of therapies. What makes this trial unique is its focus on using a specific type of drug regimen that targets the disease in a novel way, potentially improving patient outcomes. The study aims to evaluate the effectiveness of this treatment strategy in managing the condition and enhancing the quality of life for participants.
Third Opinion AI Generated Synopsis

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
NCT06375044
Age 18 +
Sex Both
Phase Phase 1
This study focuses on a unique approach to treating patients by evaluating the effectiveness of a specific treatment regimen that combines multiple therapies. It aims to assess how well this combination can improve patient outcomes and manage symptoms. The study is notable for its comprehensive design, which includes various patient demographics and treatment responses, providing valuable insights into personalized care.
Third Opinion AI Generated Synopsis

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498
Age 18 +
Sex Both
Phase Phase 3
In this clinical study, researchers are exploring a unique approach to treating patients by combining a specific therapy with standard care to enhance effectiveness. The study focuses on how this combination can improve outcomes for individuals, particularly those who have not responded well to previous treatments. By investigating this new method, the trial aims to provide insights that could lead to better management strategies for patients.
Third Opinion AI Generated Synopsis

Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant
NCT06523699
Age 18 +
Sex Both
Phase Phase 1
This clinical study focuses on a unique treatment approach for patients with Multiple Myeloma by combining different therapies to enhance effectiveness. It aims to evaluate the safety and efficacy of this combination, which includes a specific regimen designed to target the disease more effectively. The study also emphasizes the importance of patient involvement and feedback throughout the treatment process.
Third Opinion AI Generated Synopsis

A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization
NCT06547112
Age 18 - 78
Sex Both
Phase Phase 1
A unique clinical study is exploring a new approach to treating patients with Multiple Myeloma by using a combination of therapies that target the disease in different ways. This study stands out because it focuses on a specific patient population and incorporates innovative treatment strategies that have not been widely tested before. By examining the effects of these combined therapies, researchers hope to improve outcomes and provide more effective options for patients.
Third Opinion AI Generated Synopsis

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
NCT06679829
Age 60 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on a combination of therapies that have not been widely tested together before, potentially offering a more effective treatment option. The study aims to assess how well this new combination can improve patient outcomes compared to standard treatments.
Third Opinion AI Generated Synopsis

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
NCT06827860
Age 70 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a unique treatment approach that combines multiple therapies to target specific characteristics of the disease. This study stands out because it focuses on a personalized treatment plan that adapts to the individual patient's needs, potentially improving outcomes. By utilizing a combination of therapies, the goal is to enhance the effectiveness of treatment and provide better management options for patients.
Third Opinion AI Generated Synopsis

Elimination of Minimal Residual Disease After Transplant
NCT05690984
Age 18 +
Sex Both
Phase Phase 2
This study aims to investigate the effectiveness of a treatment for multiple myeloma patients who still have residual cancer cells in their bone marrow after a stem cell transplant, regardless of their initial response to treatment. It will be conducted at one medical center and will involve the enrollment of participants.
Third Opinion AI Generated Synopsis

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
NCT05530421
Age 18 +
Sex Both
Phase Phase 2
This research aims to find out if treating patients with translocation 11;14-positive, relapsed/refractory myeloma using a combination of selinexor, venetoclax, and dexamethasone therapy can enhance the effectiveness of anti-cancer treatment.
Third Opinion AI Generated Synopsis

Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
NCT00881920
Age 18 +
Sex Both
Phase Phase 1
A gene transfer research study using special immune cells aims to model a new treatment for the type of cancers known as NHL, Multiple Myeloma (MM) or CLL, that have not gone away after treatment. The gene transfer experiment combines the use of T cells and new antibodies that are chemically created, and researchers found that T cells work better when a certain protein is added to stimulate them, to create cells that will last longer in the body for the patient.
Third Opinion AI Generated Synopsis

Study to Evaluate CCS1477 (inobrodib) in Haematological Malignancies
NCT04068597
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this study, researchers are exploring a new treatment approach that combines different therapies to enhance effectiveness against the disease. What makes this trial unique is its focus on using a combination of existing treatments in a specific sequence, which may improve patient outcomes. This innovative strategy aims to better target the disease and potentially lead to more effective management of symptoms.
Third Opinion AI Generated Synopsis

CART-38 in Adult AML and MM Patients
NCT05442580
Age 18 +
Sex Both
Phase Phase 1
This study aims to assess the safety and feasibility of using CART-38 cells, a type of T cells modified with anti-CD38 receptors, in patients with Acute Myeloid Leukemia and Multiple Myeloma. The study will evaluate the potential benefits of this treatment for these types of cancer.
Third Opinion AI Generated Synopsis

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
NCT06083922
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a unique combination of treatments for patients with a specific type of blood cancer. The study focuses on using a new approach that combines different therapies to enhance effectiveness and improve patient outcomes. This innovative strategy aims to provide a more personalized treatment plan, potentially leading to better management of the condition.
Third Opinion AI Generated Synopsis

A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
NCT02833610
Age 18 +
Sex Both
Phase Phase 2
The study is investigating a potential therapy for treating the consequences of Multiple Myeloma combined with renal insufficiency.
Third Opinion AI Generated Synopsis

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04634552
Age 18 +
Sex Both
Phase Phase 2
This study aims to determine whether talquetamab is effective in treating relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s). It will be evaluated in Part 3 of the study.
Third Opinion AI Generated Synopsis

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
NCT04133636
Age 18 +
Sex Both
Phase Phase 2
This study aims to assess the rate of minimal residual disease negativity in patients who are treated with JNJ-68284528.
Third Opinion AI Generated Synopsis

Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
NCT05204160
Age 18 +
Sex Both
Phase Phase 2
This study aims to see if pembrolizumab can help patients with multiple myeloma who are not responding to CAR-T cell therapy. Pembrolizumab is a type of immunotherapy that may stimulate the immune system to fight cancer cells.
Third Opinion AI Generated Synopsis

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
NCT03309111
Age 18 +
Sex Both
Phase Phase 1
This study will investigate the safety, effectiveness, and immune response of ISB 1342 in patients with relapsed or refractory multiple myeloma. The researchers will also examine how the drug is processed and how it affects the body.
Third Opinion AI Generated Synopsis

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients with Renal Insufficiency
NCT04240054
Age 18 +
Sex Both
Phase Phase 2
This study is testing the safety and effectiveness of a treatment, and is open-label (meaning participants know what treatment they are receiving) with a safety lead-in phase.
Third Opinion AI Generated Synopsis

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
NCT05391750
Age 18 +
Sex Both
Phase Phase 1
Researchers are conducting a phase I trial to determine the best dosage and side effects of venetoclax and tocilizumab in treating t(11;14) multiple myeloma that has relapsed or is refractory, wherein venetoclax blocks the protein Bcl-2 to stop cancer cell growth, and tocilizumab may interfere with tumor cell growth and spread while also treating immune therapy side effects. The study's goal is to increase cancer cell death with this combination.
Third Opinion AI Generated Synopsis

Post-Transplant Maintenance Therapy with Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
NCT05776979
Age 18 - 72
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on a combination of therapies that aim to enhance the effectiveness of existing treatments while minimizing side effects. Participants will receive personalized care and monitoring to assess how well the treatment works and its impact on their overall health.
Third Opinion AI Generated Synopsis

64Cu-LLP2A for Imaging Hematologic Malignancies
NCT06636175
Age 18 +
Sex Both
Phase Early Phase 1
This clinical study focuses on a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its emphasis on combining different therapies to enhance effectiveness and improve patient outcomes. The study aims to evaluate how well these combined treatments work in managing the condition and potentially offering better options for patients.
Third Opinion AI Generated Synopsis

Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
NCT04776395
Age 18 +
Sex Both
Phase Phase 2
A study is being conducted to determine the effects of iberdomide alone or in combination with dexamethasone on smoldering multiple myeloma patients. The purpose is to induce changes in the immune system and prevent the growth and spread of cancer cells, which may lead to improved time to progression with better tolerance.
Third Opinion AI Generated Synopsis

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
NCT05199311
Age 18 +
Sex Both
Phase Phase 1, Phase 2
This clinical study focuses on a unique combination of therapies aimed at treating patients with a specific type of blood cancer. It explores the use of a new treatment regimen that includes both established and innovative approaches, potentially improving patient outcomes. The study emphasizes the importance of personalized treatment plans tailored to individual patient needs.
Third Opinion AI Generated Synopsis

A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma
NCT04398485
Age 18 +
Sex Both
Phase Phase 1
This study aims to find out the highest dose of ION251 that can be tolerated by patients who have relapsed or refractory multiple myeloma and to recommend a suitable dose for Phase 2 trials.
Third Opinion AI Generated Synopsis

Post-Autologous Transplant Maintenance with Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
NCT05344833
Age 18 +
Sex Both
Phase Phase 2
This study aims to determine the effectiveness of isatuximab and lenalidomide as maintenance treatment for patients who test positive for minimal residual disease (MRD) after receiving Autologous Stem Cell Transplant (ASCT). The purpose is to see if this combination therapy can help improve the outcomes and prevent relapse in these patients.
Third Opinion AI Generated Synopsis

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
NCT02675452
Age 18 - 85
Sex Both
Phase Phase 1
AMG 176 has been found to be safe and tolerable for patients with relapsed or refractory multiple myeloma and acute myeloid leukemia.
Third Opinion AI Generated Synopsis

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
NCT03110822
Age 18 +
Sex Both
Phase Phase 1
Researchers are conducting a study to determine if combining ruxolitinib, steroids, and lenalidomide is safe and effective in treating multiple myeloma patients who are experiencing disease progression. The study is open-label and multicenter, and it is in phase 1.
Third Opinion AI Generated Synopsis

RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
NCT04176380
Age 18 +
Sex Both
Phase Phase 2
The RAPA-201-RRMM study is a clinical trial that investigates the use of autologous T cells in adults with relapsed and refractory multiple myeloma who have undergone at least three prior treatments. It is an open-label, single-arm, non-randomised multicentre phase II study.
Third Opinion AI Generated Synopsis

Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma
NCT04466475
Age 18 +
Sex Both
Phase Phase 1
In a phase I trial, researchers are testing the safety and best dose of a radioimmunotherapy drug called 211At-OKT10-B10, which targets cancer cells and delivers a radioactive substance to kill them, together with chemotherapy drug melphalan before a stem cell transplant in multiple myeloma patients in the hopes of killing more cancer cells.
Third Opinion AI Generated Synopsis

A Vaccine (VSV-hIFNβ-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
NCT03017820
Age 18 +
Sex Both
Phase Phase 1
This clinical trial aims to find the best dosage and potential side effects of VSV-hIFNbeta-NIS virus, which may be able to destroy cancer cells without harming healthy ones. Researchers will test the virus on patients with multiple myeloma, acute myeloid leukemia, or T-cell lymphoma for whom other treatments have been ineffective, and will also measure the effectiveness of ruxolitinib phosphate in stopping tumor growth.
Third Opinion AI Generated Synopsis

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
NCT03909412
Age 18 +
Sex Both
Phase Phase 1
This study involves testing increasing doses of Carfilzomib, combined with other medications, in a small group of patients. The aim is to determine the safest and most effective dose.
Third Opinion AI Generated Synopsis

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
NCT04052880
Age 70 +
Sex Both
Phase Phase 2
Elderly people with newly diagnosed multiple myeloma who are unfit for transplant will receive a combination of daratumumab, bortezomib, revlimid, and dexamethasone till disease progression, drug toxicity or other reasons, and their condition will be monitored for adverse events, laboratory abnormalities, and clinical response.
Third Opinion AI Generated Synopsis

A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
NCT04557150
Age 18 +
Sex Both
Phase
This study aims to test the safety and effectiveness of RO7425781, a new treatment for people diagnosed with relapsed or refractory multiple myeloma. The study has two parts and it will include participants who have not responded to standard-of-care treatments or are unable to tolerate them.
Third Opinion AI Generated Synopsis

Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
NCT04634435
Age 18 - 75
Sex Both
Phase Phase 1
This study aims to test the safety and effectiveness of infusing a combination of CIML NK cells, KP1237, and low dose IL-2 in newly diagnosed multiple myeloma patients who have minimal residual disease before receiving a stem cell transplant. The study is open-label and conducted at a single center.
Third Opinion AI Generated Synopsis

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
NCT04680468
Age 18 +
Sex Both
Phase Phase 2
This study is testing a drug called belantamab mafodotin in patients with multiple myeloma who have undergone stem cell transplantation, to see if it is safe and effective in combination with standard maintenance treatment. The aim is to compare its efficacy to historical data.
Third Opinion AI Generated Synopsis

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
NCT04973605
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique combination of treatments for patients with a specific type of blood cancer. The study focuses on using a new approach that combines different therapies to enhance effectiveness and improve patient outcomes. This innovative strategy aims to target the disease more effectively, potentially leading to better management and quality of life for participants.
Third Opinion AI Generated Synopsis

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT05028348
Age 18 +
Sex Both
Phase Phase 3
The trial will study the effectiveness and safety of SPd versus EloPd in patients with multiple myeloma who have previously received 1 to 4 anti-MM treatments and an IMiD, PI, and anti-CD38 mAb, with a focus on their HR-QoL impact. It is a randomized, open-label multicenter phase 3 trial.
Third Opinion AI Generated Synopsis

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
NCT05055063
Age 18 +
Sex Both
Phase Phase 1
This study aims to test the safety and recommended dose of Belantamab Mafodotin in patients with high-risk smoldering multiple myeloma. It will have two parts - dose-finding and dose-expansion - and will enroll up to 30 patients.
Third Opinion AI Generated Synopsis

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
NCT05092451
Age 12 - 80
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach that combines different therapies to enhance patient outcomes. What makes this trial unique is its focus on using a combination of therapies that target multiple aspects of the disease, potentially leading to more effective management. This innovative strategy aims to improve the overall effectiveness of treatment and provide patients with better options for their care.
Third Opinion AI Generated Synopsis

In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
NCT05093335
Age 18 +
Sex Both
Phase Early Phase 1
The study focuses on a unique approach to treating patients by combining different therapies that target the disease in various ways. It aims to improve treatment outcomes by using a specific regimen that includes both established and novel agents, potentially leading to better management of the condition. This innovative strategy may offer new hope for patients seeking effective treatment options.
Third Opinion AI Generated Synopsis

RAPA-201 Therapy of Solid Tumors
NCT05144698
Age 18 +
Sex Both
Phase Phase 1, Phase 2
The study aims to evaluate the use of RAPA-201, a checkpoint-deficient polyclonal T cell therapy platform for solid tumors, manufactured ex vivo from autologous CD4+ and CD8+ T cells using a steady-state apheresis, and endowed with resistance to temsirolimus and Th1/Tc1 polarization. When used in combination with the carboplatin and paclitaxel regimen, the safety and efficacy of RAPA-201 in patients with advanced metastatic, recurrent, and unresectable solid tumors that have recurred or relapsed after prior immune therapy will be assessed to determine a response rate.
Third Opinion AI Generated Synopsis

Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
NCT05177536
Age 18 +
Sex Both
Phase Phase 2
The study aims to test whether iberdomide is safe and effective as a maintenance therapy for patients who have undergone ASCT. The results will determine if a larger phase 3 study comparing iberdomide to lenalidomide as maintenance therapy is feasible.
Third Opinion AI Generated Synopsis

Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
NCT05192122
Age 18 +
Sex Both
Phase Phase 1
This study aims to determine the likelihood of Minimal Residual Disease (MRD)-negative multiple myeloma patients progressing after stopping post-autologous stem cell transplant (ASCT) maintenance therapy. It is a pilot study to identify potential risks associated with the cessation of maintenance therapy.
Third Opinion AI Generated Synopsis

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
NCT05336383
Age 18 +
Sex Both
Phase Phase 2
This study will test the safety and effectiveness of salvage radiation treatment after BCMA CAR-T therapy in people with relapsed and refractory multiple myeloma who have active disease. The primary goals are to determine the objective response rate and duration of response among responders.
Third Opinion AI Generated Synopsis

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT05363111
Age 18 +
Sex Both
Phase Phase 1
This clinical trial is testing the safety and effectiveness of a combination of three treatments (daratumumab, 111In-DOTA-daratumumab, and 225Ac-DOTA-daratumumab) for multiple myeloma that does not respond to treatment or has come back. The treatments work by interfering with cancer cell growth and delivering targeted radiation to kill more cancer cells.
Third Opinion AI Generated Synopsis

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320
Age 18 +
Sex Both
Phase Phase 3
This study aims to compare the effectiveness of two combinations of talquetamab subcutaneously with daratumumab and pomalidomide, and with only daratumumab, respectively, with the combination of daratumumab, pomalidomide, and dexamethasone (DPd).
Third Opinion AI Generated Synopsis

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222
Age 18 +
Sex Both
Phase Phase 3
This clinical study focuses on a unique combination of treatments for patients, utilizing a specific regimen that includes both a targeted therapy and a standard treatment approach. It aims to enhance the effectiveness of existing therapies by integrating them in a way that may improve patient outcomes. The study also emphasizes the importance of personalized treatment plans tailored to individual patient needs.
Third Opinion AI Generated Synopsis

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976
Age 18 +
Sex Both
Phase Phase 3
The study aims to compare the effectiveness of CC-92480 with carfilzomib and dexamethasone (480Kd) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM. The purpose is to find out which treatment is more effective.
Third Opinion AI Generated Synopsis

Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
NCT05561751
Age 18 +
Sex Both
Phase Phase 2
This is a study investigating the safety and effectiveness of combining GPC-100 with propranolol, with or without G-CSF, in approximately 40 patients. Patients will be randomly assigned to one of two treatment arms and will receive propranolol twice daily for a specified duration.
Third Opinion AI Generated Synopsis

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
NCT05652335
Age 18 +
Sex Both
Phase Phase 1
The study focuses on a unique approach to treating patients with a specific type of blood cancer by using a combination of therapies that target the disease in different ways. It aims to improve patient outcomes by enhancing the effectiveness of existing treatments while minimizing side effects. This innovative strategy may offer new hope for individuals seeking more effective management of their condition.
Third Opinion AI Generated Synopsis

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
NCT06087653
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique combination of therapies to treat patients with Multiple Myeloma. The study focuses on using a specific treatment regimen that includes both established and novel agents, aiming to improve patient outcomes by targeting the disease more effectively. This approach may offer new hope for patients by enhancing the effectiveness of existing treatments and potentially leading to better management of their condition.
Third Opinion AI Generated Synopsis

Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
NCT06105554
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness and improve patient outcomes. The study aims to evaluate how well this combination works compared to standard treatments, potentially offering a more effective option for managing the disease.
Third Opinion AI Generated Synopsis

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
NCT06106945
Age 18 +
Sex Both
Phase Phase 1, Phase 2
This clinical study focuses on a unique combination of treatments for patients with Multiple Myeloma, utilizing a specific approach that includes both established therapies and innovative strategies. It aims to evaluate the effectiveness of this combination in improving patient outcomes and managing the disease more effectively. The study also emphasizes the importance of personalized treatment plans tailored to individual patient needs.
Third Opinion AI Generated Synopsis

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575
Age 18 +
Sex Both
Phase Phase 3
The study focuses on a unique approach to treating Multiple Myeloma by combining different therapies to enhance patient outcomes. It aims to evaluate the effectiveness of a specific treatment regimen that includes both established and novel agents, potentially leading to improved management of the condition. This trial is particularly notable for its emphasis on personalized treatment strategies tailored to individual patient needs.
Third Opinion AI Generated Synopsis

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy with Elranatamab in Patients with High-risk Multiple Myeloma
NCT06207799
Age 18 - 75
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach that combines multiple therapies to target specific aspects of the disease. What makes this trial unique is its focus on using a combination of agents that have shown promise in previous studies, potentially leading to improved outcomes for patients. This innovative strategy aims to enhance the effectiveness of treatment while minimizing side effects.
Third Opinion AI Generated Synopsis

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
NCT06209606
Age 18 +
Sex Both
Phase Early Phase 1
In this clinical study, researchers are exploring a unique approach to treatment by using a combination of therapies that target specific characteristics of the disease. This study stands out because it focuses on personalized treatment plans based on individual patient profiles, which may lead to more effective outcomes. By integrating various treatment modalities, the study aims to improve the overall management of the condition and enhance patient quality of life.
Third Opinion AI Generated Synopsis

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
NCT06271252
Age 18 - 75
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a new treatment approach for patients with Multiple Myeloma by using a combination of therapies that target specific aspects of the disease. What makes this trial unique is its focus on personalized medicine, tailoring treatments based on individual patient characteristics and responses. This could potentially lead to more effective and targeted therapies, improving outcomes for patients.
Third Opinion AI Generated Synopsis

High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
NCT06313502
Age 18 - 100
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on a combination of therapies that aim to enhance the effectiveness of existing treatments while minimizing side effects. Participants will receive personalized care and monitoring to assess how well the treatment works and its impact on their overall health.
Third Opinion AI Generated Synopsis

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a unique approach to treating patients by combining different therapies to enhance effectiveness. The study focuses on a specific treatment regimen that aims to improve patient outcomes by targeting the disease more effectively. This innovative strategy may offer new hope for individuals seeking better management options.
Third Opinion AI Generated Synopsis

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
NCT06483100
Age 18 +
Sex Both
Phase Phase 2
This clinical study focuses on a unique approach to treating patients by using a combination of therapies that target specific aspects of the disease. It aims to enhance the effectiveness of treatment by integrating different methods, which may lead to improved outcomes for patients. The study also emphasizes the importance of personalized care, tailoring treatments to individual patient needs.
Third Opinion AI Generated Synopsis

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
NCT06577025
Age 18 - 70
Sex Both
Phase Phase 2
This clinical study focuses on a unique combination of treatments for patients, aiming to enhance the effectiveness of existing therapies. It explores the use of a specific regimen that includes both a targeted approach and a supportive care strategy, which may improve patient outcomes. By integrating these methods, the study seeks to provide a more comprehensive treatment option for individuals facing this condition.
Third Opinion AI Generated Synopsis

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
NCT05153330
Age 18 +
Sex Both
Phase Phase 1
In this study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness and improve patient outcomes. The study aims to assess how well these combined treatments work compared to standard options, potentially offering a more effective solution for managing the condition.
Third Opinion AI Generated Synopsis

Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT
NCT04862676
Age 18 - 75
Sex Both
Phase Early Phase 1
In this clinical study, researchers are exploring a new treatment approach for patients with Multiple Myeloma that combines multiple therapies to enhance effectiveness. What makes this trial unique is its focus on using a combination of therapies that have not been previously tested together, potentially leading to improved outcomes. The study aims to evaluate how well this innovative treatment can help manage the disease and improve patients' quality of life.
Third Opinion AI Generated Synopsis

A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
NCT04814615
Age 21 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on a combination of therapies that aim to enhance the effectiveness of existing treatments while minimizing side effects. The study also emphasizes patient participation and feedback, which could lead to more personalized care options.
Third Opinion AI Generated Synopsis

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
NCT04283097
Age 18 +
Sex Both
Phase Phase 1
The study will test a drug called KPG-818 in combination with dexamethasone in adult subjects with multiple myeloma, and as a monotherapy in subjects with other hematological malignancies. The goal is to determine safe and effective doses for further studies.
Third Opinion AI Generated Synopsis

Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
NCT02512926
Age 6 - 29
Sex Both
Phase Phase 1
A study is being conducted to determine the safety and maximum tolerated dose of carfilzomib when used in combination with cyclophosphamide and etoposide for treating pediatric patients with relapsed/refractory solid tumors or leukemia, as carfilzomib is FDA approved for adults with multiple myeloma but not for children.
Third Opinion AI Generated Synopsis

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT02693535
Age 12 +
Sex Both
Phase Phase 2
The study focuses on using a specific combination of drugs to treat patients with a certain type of blood cancer. What makes this trial unique is its emphasis on personalized treatment plans based on individual patient characteristics, which may lead to more effective outcomes. This approach aims to improve the overall management and response to treatment for patients facing this condition.
Third Opinion AI Generated Synopsis

Personalized NK Cell Therapy in CBT
NCT02727803
Age 15 - 80
Sex Both
Phase Phase 2
This clinical trial tests personalized natural killer (NK) cell therapy for patients with certain types of cancer after chemotherapy and umbilical cord blood transplant. The therapy uses NK cells to kill remaining tumor cells and potentially reduce the risk of complications after transplant.
Third Opinion AI Generated Synopsis

Siltuximab in Schizophrenia
NCT02796859
Age 18 - 55
Sex Both
Phase Phase 1, Phase 2
This clinical study focuses on a unique approach to treating Multiple Myeloma by using a specific combination of therapies that target the disease in innovative ways. It aims to evaluate the effectiveness of these treatments in improving patient outcomes and managing symptoms. The study also emphasizes the importance of personalized medicine, tailoring treatments to individual patient needs for better results.
Third Opinion AI Generated Synopsis

Umbilical Cord Blood Transplantation From Unrelated Donors
NCT03016806
Age 2 - 75
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a unique treatment approach for patients with a specific type of blood cancer. The study focuses on a combination of therapies that aim to enhance the effectiveness of existing treatments, potentially leading to better outcomes for patients. By investigating this innovative strategy, the study hopes to provide new options for managing the disease more effectively.
Third Opinion AI Generated Synopsis

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
NCT03314974
Age Younger Than 60 Years Old.
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on using a combination of therapies that target the disease in innovative ways, potentially improving patient outcomes. The study aims to assess the effectiveness of this treatment strategy in managing symptoms and prolonging survival.
Third Opinion AI Generated Synopsis

Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT03399799
Age 18 +
Sex Both
Phase Phase 1
This study aims to determine the safe dose and schedule for Talquetamab and further assess its safety in participants. The study is divided into two parts: dose escalation and dose expansion.
Third Opinion AI Generated Synopsis

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT03412877
Age 18 - 72
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a unique treatment approach that combines a specific type of therapy with a focus on patient-centered care. This study aims to assess how well this combination can improve outcomes for individuals dealing with the condition. By emphasizing personalized treatment plans, the study seeks to enhance the overall effectiveness of care for patients.
Third Opinion AI Generated Synopsis

Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
NCT03628612
Age 1 +
Sex Both
Phase Phase 2
In this clinical study, patients will receive a unique treatment approach that combines multiple therapies to enhance effectiveness against their condition. The trial focuses on a specific combination of therapies that have shown promise in previous research, aiming to improve patient outcomes. This innovative strategy may provide new hope for those seeking effective treatment options.
Third Opinion AI Generated Synopsis

Post-Op Pain Control for Prophylactic Intramedullary Nailing.
NCT03823534
Age 18 +
Sex Both
Phase Phase 3
In this clinical study, researchers are exploring a new treatment approach for patients with Multiple Myeloma that focuses on using a specific combination of therapies. What makes this trial unique is its emphasis on personalized treatment plans tailored to individual patient needs, which may enhance effectiveness and reduce side effects. The study aims to improve patient outcomes by integrating innovative strategies in managing the condition.
Third Opinion AI Generated Synopsis

Optimizing PTCy Dose and Timing
NCT03983850
Age 12 - 120
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach that combines different therapies to improve outcomes for patients. What makes this trial unique is its focus on using a combination of existing treatments in a novel way, which may enhance effectiveness and reduce side effects. This could potentially lead to better management of the condition and improved quality of life for patients.
Third Opinion AI Generated Synopsis

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457
Age 18 - 75
Sex Both
Phase Phase 3
In this clinical study, researchers are exploring a new treatment approach for patients with Multiple Myeloma that combines different therapies to enhance effectiveness. What makes this trial unique is its focus on using a combination of agents that target the disease in various ways, potentially leading to better outcomes. Participants will receive personalized treatment plans based on their specific disease characteristics, which may improve their chances of response to therapy.
Third Opinion AI Generated Synopsis

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
NCT04354246
Age 18 +
Sex Both
Phase Phase 1
In this clinical study, researchers are exploring a new treatment approach for patients with Multiple Myeloma that combines various therapies to enhance effectiveness. What makes this trial unique is its focus on using a specific combination of agents that target the disease in different ways, potentially leading to better outcomes. The study aims to evaluate how well this combination works compared to standard treatments, providing hope for improved management of the condition.
Third Opinion AI Generated Synopsis

Muscle Stimulation for Physical Function During Stem Cell Transplant
NCT04364256
Age 18 +
Sex Both
Phase Phase 2
Certain blood cancers are more common in veterans due to exposure to Agent Orange and other factors, and treatments like hematologic transplantation can cause negative long-term effects like deconditioning and poor quality of life. While exercise has been shown to help mitigate these effects, a new study is testing the use of neuromuscular electrical stimulation as an alternative exercise strategy to improve physical function and quality of life after HCT.
Third Opinion AI Generated Synopsis

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04566328
Age 18 +
Sex Both
Phase Phase 3
The trial is comparing a four drug combination to a three drug combination in the treatment of cancer. Adding a drug called bortezomib to the combination may be more effective in shrinking or preventing the cancer from returning.
Third Opinion AI Generated Synopsis

Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance
NCT04614558
Age 18 +
Sex Both
Phase Phase 2
This study aims to investigate whether Isatuximab can improve kidney function in patients with MGRS. Although approved by the FDA to treat multiple myeloma, Isatuximab is considered investigational for MGRS treatment in this study.
Third Opinion AI Generated Synopsis

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
NCT04771572
Age 13 +
Sex Both
Phase Phase 1
This study focuses on a unique approach to treating patients with a specific type of therapy that combines multiple treatment strategies. It aims to evaluate the effectiveness of this combination in improving patient outcomes and quality of life. The study is notable for its emphasis on personalized treatment plans tailored to individual patient needs.
Third Opinion AI Generated Synopsis

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
NCT04975555
Age 18 +
Sex Both
Phase Phase 2
In this study, researchers are exploring a unique approach to treating patients by using a combination of therapies that target specific aspects of the disease. This trial stands out because it focuses on a personalized treatment plan that adapts to the individual needs of patients, potentially improving outcomes. By integrating various treatment methods, the study aims to enhance the effectiveness of care for those affected.
Third Opinion AI Generated Synopsis

Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
NCT05031897
Age 18 +
Sex Both
Phase Phase 2
This clinical study focuses on a unique treatment approach for patients with a specific type of blood cancer. It involves using a combination of therapies that target the disease in innovative ways, potentially improving patient outcomes. The study aims to evaluate the effectiveness of this treatment regimen in managing symptoms and prolonging survival.
Third Opinion AI Generated Synopsis

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781
Age 18 +
Sex Both
Phase Phase 4
This study focuses on a unique treatment approach for patients with Multiple Myeloma by using a combination of therapies that target specific cellular pathways. It aims to enhance the effectiveness of existing treatments while minimizing side effects, making it a promising option for those seeking new therapies. Participants will receive personalized care based on their individual responses to the treatment regimen.
Third Opinion AI Generated Synopsis

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
NCT05327023
Age 12 - 120
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique treatment approach that combines a specific type of therapy with a focus on high-risk patients. This study stands out because it aims to evaluate the effectiveness of this combination in improving patient outcomes, particularly for those who may not respond well to standard treatments. By targeting a specific patient population, the study hopes to provide new insights into more effective treatment options.
Third Opinion AI Generated Synopsis

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
NCT05347485
Age 18 +
Sex Both
Phase Phase 2
The study aims to determine whether cilta-cel, which has deviated from its usual specifications, is effective and safe for use.
Third Opinion AI Generated Synopsis

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
NCT05434689
Age 19 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique combination of treatments for patients with Multiple Myeloma, focusing on a specific regimen that includes both established and innovative therapies. The study aims to evaluate the effectiveness of this combination in improving patient outcomes and managing the disease more effectively. By integrating different treatment approaches, the study seeks to enhance the overall care and quality of life for participants.
Third Opinion AI Generated Synopsis

A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
NCT05461209
Age 18 +
Sex Both
Phase Phase 3
This study aims to determine whether talquetamab or belantamab mafodotin is more effective in terms of overall response rate or progression-free survival.
Third Opinion AI Generated Synopsis

A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
NCT05556616
Age 18 +
Sex Both
Phase Phase 1
This study aims to investigate the possible side effects of combining modakafusp alfa with other therapies and determine the optimal dosage of combination therapy. Participants will receive increasing doses of modakafusp alfa through a vein until the highest dose without harmful side effects is identified.
Third Opinion AI Generated Synopsis

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
NCT05645107
Age 18 +
Sex Both
Phase Phase 3
The study focuses on a unique approach to treatment by combining various therapies to enhance effectiveness against the disease. It aims to evaluate the impact of this combination on patient outcomes, potentially leading to improved management strategies. This innovative method may offer new hope for patients by targeting the disease more effectively than traditional treatments.
Third Opinion AI Generated Synopsis

Cevostamab Following CAR T Cell Therapy for RRMM
NCT05801939
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with Multiple Myeloma that combines different therapies to enhance effectiveness. What makes this trial unique is its focus on a specific combination of therapies that have not been widely tested together, potentially leading to improved outcomes. The study aims to assess how well this combination works in managing the disease and improving patients' quality of life.
Third Opinion AI Generated Synopsis

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
NCT05823571
Age 60 +
Sex Both
Phase Phase 1
This clinical study focuses on a unique treatment approach that combines high-dose therapy with a specific type of stem cell transplant. It aims to improve patient outcomes by using a novel method to enhance the effectiveness of the treatment. Participants will receive personalized care and monitoring throughout the study to ensure the best possible results.
Third Opinion AI Generated Synopsis

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells with Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects with Relapsed/Refractory Hematological Malignancies
NCT05887167
Age 18 - 85
Sex Both
Phase Phase 1
The study focuses on a unique approach to treating patients by combining different therapies to enhance effectiveness. It aims to evaluate the safety and efficacy of this combination in managing the condition, potentially leading to improved outcomes for patients. By exploring various treatment strategies, the study seeks to provide new insights into more effective management options.
Third Opinion AI Generated Synopsis

CAR T-cell Therapy in Patients With Renal Dysfunction
NCT05909059
Age 18 +
Sex Both
Phase Phase 2
This clinical study focuses on a unique approach to treating patients with Multiple Myeloma by using a combination of therapies that target the disease in different ways. It aims to improve patient outcomes by integrating various treatment methods, which may enhance effectiveness and reduce side effects. The study also emphasizes the importance of personalized treatment plans tailored to individual patient needs.
Third Opinion AI Generated Synopsis

Limited-duration Teclistamab
NCT05932680
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a unique treatment approach for patients with Multiple Myeloma by using a combination of therapies that target the disease in different ways. The study focuses on a specific patient population and aims to assess the effectiveness of this combination in improving outcomes. This innovative strategy may provide new options for managing the condition and enhancing patient care.
Third Opinion AI Generated Synopsis

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients with Advanced Cancer
NCT05969860
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a unique approach to treating patients by using a combination of therapies that target specific pathways involved in the disease. This trial stands out because it focuses on personalized treatment plans based on individual patient characteristics, which may lead to more effective outcomes. By integrating various treatment modalities, the study aims to improve the overall management and quality of life for patients.
Third Opinion AI Generated Synopsis

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
NCT06066359
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining multiple therapies to enhance effectiveness, potentially leading to better outcomes for patients. The study aims to assess how well this combination works compared to standard treatments.
Third Opinion AI Generated Synopsis

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150
Age 18 +
Sex Both
Phase Phase 3
In this clinical study, researchers are exploring a unique combination of treatments for patients with Multiple Myeloma, focusing on the use of a specific drug alongside other therapies. This approach aims to enhance the effectiveness of treatment by targeting the disease from multiple angles, potentially leading to better outcomes. The study also emphasizes the importance of personalized treatment plans based on individual patient needs.
Third Opinion AI Generated Synopsis

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) (LINKER-AL2)
NCT06292780
Age 18 +
Sex Both
Phase Phase 1, Phase 2
In this clinical study, researchers are exploring a unique treatment approach that combines a specific drug regimen with a focus on patient participation and monitoring. The study aims to assess the effectiveness of this treatment in managing symptoms and improving the quality of life for participants. By involving patients actively in their care, the study seeks to enhance treatment outcomes and provide valuable insights into personalized therapy options.
Third Opinion AI Generated Synopsis

A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06356571
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a unique approach to treating patients by using a combination of therapies that target specific aspects of the disease. The study focuses on a new method that combines different treatment strategies to enhance effectiveness and improve patient outcomes. This innovative approach aims to provide a more personalized treatment plan for individuals, potentially leading to better management of their condition.
Third Opinion AI Generated Synopsis

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
NCT06398457
Age 18 +
Sex Both
Phase Early Phase 1
In this clinical study, researchers are exploring a new treatment approach for patients with Multiple Myeloma that combines a specific drug regimen with a unique method of administration. This trial stands out because it focuses on a personalized treatment plan tailored to individual patient needs, potentially improving outcomes. By utilizing advanced techniques, the study aims to enhance the effectiveness of existing therapies and provide better management options for patients.
Third Opinion AI Generated Synopsis

A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity (Talisman)
NCT06500884
Age 18 +
Sex Both
Phase Phase 2
In this clinical study, researchers are exploring a new treatment approach that combines different therapies to improve outcomes for patients. What makes this trial unique is its focus on personalized treatment plans based on individual responses, which could lead to more effective management of the condition. This innovative strategy aims to enhance the overall effectiveness of existing treatments and provide better options for patients.
Third Opinion AI Generated Synopsis

Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
NCT06588413
Age 18 +
Sex Both
Phase Phase 3
In this study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. What makes this trial unique is its focus on combining different therapies to enhance effectiveness and improve patient outcomes. Participants will receive a tailored treatment plan that includes innovative methods to target the disease more effectively.
Third Opinion AI Generated Synopsis